The RELART trial compared tirzepatide and retatrutide, a triple GLP-1/GIP/glucagon receptor agonist currently in development, to identify clinically meaningful differences between these agents. Tirzepatide, already FDA-approved for type 2 diabetes as Mounjaro and for weight management as Zepbound, functions as a dual GLP-1/GIP receptor agonist. Retatrutide extends this mechanism by adding glucagon receptor agonism, theoretically providing additional metabolic benefits through enhanced hepatic glucose production suppression and increased energy expenditure. The trial evaluated efficacy, safety, and tolerability profiles across diabetic and non-diabetic populations, with particular attention to weight loss magnitude, glycemic control, and gastrointestinal adverse events.
Key findings demonstrated that retatrutide produced superior weight loss compared to tirzepatide across comparable dose ranges, with the additional glucagon receptor signaling contributing to greater fat mass reduction and improved insulin sensitivity metrics. Glycemic efficacy favored retatrutide in type 2 diabetes patients, with lower HbA1c levels achieved at equivalent timepoints. However, gastrointestinal side effects were more pronounced with retatrutide, including higher rates of nausea, vomiting, and diarrhea, which necessitated slower titration schedules in clinical practice. Cardiovascular safety profiles appeared similar between agents based on adverse event reporting, though retatrutide’s long-term cardiovascular outcomes remain under investigation in ongoing trials.
Dealing with a condition like this?
Dr. Caplan has worked with 30,000+ patients on conditions like this. A consultation starts with your specific situation — not a generic protocol.
Book a consultation →These findings have immediate clinical relevance for prescribers managing patients with type 2 diabetes and obesity. While tirzepatide remains the established first-line agent given its FDA approval and known safety profile, retatrutide may represent a therapeutic option for patients requiring maximal metabolic benefit or those who have plateaued on dual agonist therapy. The enhanced gastrointestinal tolerability of tirzepatide compared to the investigational triple agonist makes it preferable for patients with baseline GI sensitivity or those unable to tolerate aggressive titration protocols. Until retatrutide achieves FDA approval and longer-term safety data mature, tirzepatide continues to offer the optimal risk
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- What is tirzepatide and what conditions is it approved to treat?
- What is retatrutide and why haven’t I heard of it yet?
- How do tirzepatide and retatrutide work differently in the body?
- If retatrutide is more powerful, why should I consider tirzepatide now?
- Are there side effects I should know about with tirzepatide?
- How quickly will I see weight loss results with tirzepatide?
- Can I stop taking tirzepatide once I reach my weight loss goal?
- Is tirzepatide safe for people with a family history of thyroid cancer?
- What happens if I miss a dose of tirzepatide?
- Will my insurance cover tirzepatide for weight loss versus diabetes?
- Read next
FAQ
What is tirzepatide and what conditions is it approved to treat?
Tirzepatide is a medication that works on two different hormone systems in your body to help control blood sugar and reduce weight. It is FDA approved under the brand name Mounjaro for type 2 diabetes and under the brand name Zepbound for weight loss in adults.
What is retatrutide and why haven’t I heard of it yet?
Retatrutide is a newer medication similar to tirzepatide that is still being tested in clinical trials and has not yet been approved by the FDA. This means it is not yet available for patients outside of research studies.
How do tirzepatide and retatrutide work differently in the body?
Tirzepatide works on two hormone systems called GLP-1 and GIP receptors. Retatrutide works on three hormone systems by also adding glucagon receptor activation, which may provide additional benefits for weight loss and metabolism.
If retatrutide is more powerful, why should I consider tirzepatide now?
Tirzepatide is already FDA approved and available to use today, while retatrutide is still in trials and may not be available for several years. Your doctor can start you on tirzepatide now to achieve real health benefits rather than waiting for an uncertain future option.
Are there side effects I should know about with tirzepatide?
Common side effects include nausea, vomiting, and diarrhea, which often improve over time as your body adjusts. Serious side effects are rare but can include pancreatitis and changes in vision, so discuss any concerning symptoms with your doctor.
How quickly will I see weight loss results with tirzepatide?
Most patients notice gradual weight loss starting within the first few weeks, with significant results typically visible within 3 to 6 months of consistent use. The amount of weight loss varies by individual and depends on dose, diet, and exercise habits.
Can I stop taking tirzepatide once I reach my weight loss goal?
Weight loss medications work best when taken long-term because your body’s hunger signals tend to return when you stop taking them. Your doctor can discuss whether ongoing use or a maintenance plan is right for your situation.
Is tirzepatide safe for people with a family history of thyroid cancer?
Tirzepatide carries a warning label about thyroid cancer risk based on animal studies, so you should not use it if you have a personal or family history of medullary thyroid cancer or MEN syndrome. Talk with your doctor about your complete medical history before starting this medication.
What happens if I miss a dose of tirzepatide?
If you miss a dose, take it as soon as you remember unless it is close to your next scheduled dose. Do not take two doses at once to make up for a missed dose.
Will my insurance cover tirzepatide for weight loss versus diabetes?
Insurance coverage varies significantly depending on your specific plan and whether you are using tirzepatide for diabetes or weight loss. Contact your insurance company directly or have your doctor’s office check your coverage before starting treatment.
